Ascendis Pharma Endocrinology Division A/S

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ascendis Pharma Endocrinology Division A/S sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 4 completed later-stage tilt upper quartile by trial count

Ascendis Pharma Endocrinology Division A/S: 7 sponsored US clinical trials, 2 recruiting.

Ascendis Pharma Endocrinology Division A/S sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Growth Hormone Deficiency, with 3 trials.

Upper-quartile sponsor footprint

Ascendis Pharma Endocrinology Division A/S sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
RECRUITING

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT05775523
ACTIVE NOT RECRUITING Phase 2

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

NCT05690386
COMPLETED Phase 3

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855
COMPLETED Phase 3

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
COMPLETED Phase 3

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
COMPLETED Phase 3

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

NCT02781727

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4

Therapeutic Areas

Growth Hormone Deficiency 3
Hormone Deficiency 1
Turner Syndrome 1
Endocrine System Diseases 1

Where Ascendis Pharma Endocrinology Division A/S enrollment is open (later-stage tilt)

2 recruiting of 7 indexed (29% open); 4 completed (57%).

Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Growth Hormone Deficiency (3 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ascendis Pharma Endocrinology Division A/S: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Ascendis Pharma Endocrinology Division A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Ascendis Pharma Endocrinology Division A/S3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Ascendis Pharma Endocrinology Division A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ascendis Pharma Endocrinology Division A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ascendis Pharma Endocrinology Division A/S page

7 registered trials is a research-attention snapshot, not an endorsement of Ascendis Pharma Endocrinology Division A/S or any single study.

  • 2 of Ascendis Pharma Endocrinology Division A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Growth Hormone Deficiency is the condition Ascendis Pharma Endocrinology Division A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Growth Hormone Deficiency trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ascendis Pharma Endocrinology Division A/S pipeline card: 7 registered trials from official public datasets.Report a data error.